EFFECT ·Filed May 4, 2026
CD

CDTTW

CDT Equity Inc.
BEARISH
Impact 6/10
Horizonweeks Processed5mo ago SEC9999999995-26-001441
IPO/offering going effective
Actionable Insight ▼ Bearish

Monitor for trading volume spikes or Form 4 filings indicating insider/selling stockholder sales. The active shelf gives the company and selling stockholders flexibility to sell at any time, likely pressuring the stock. Watch for any announcements of takedowns under the equity line with Ascent Partners.

DirectionBearish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
CDTTW ▲ +104.55% at T+60d
SHORT call ✗ call lost -104.55% · α vs SPY -102.69% · entry $0.006600 → $0.0135
Entry anchored
May 4, 2026
via day open
T+1d
0.00%
call 0.00% · α +0.80%
$0.006600
settled 5mo ago
T+5d
0.00%
call 0.00% · α +2.94%
$0.006600
settled 5mo ago
T+20d
0.00%
call 0.00% · α +5.65%
$0.006600
settled 4mo ago
T+60d
+104.55%
call -104.55% · α -102.69%
$0.0135
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

CDT Equity Inc.'s shelf registration (S-3, File No. 333-295226) became effective on May 1, 2026, enabling selling stockholders to resell shares registered under prior filings. This includes up to 22.8 million shares from the January 2026 S-3 and 5.3 million shares from the April 2026 S-3, creating significant dilution overhang for a micro-cap pharmaceutical company.

Key Facts

  • Effectiveness date: May 1, 2026
  • Registration statement S-3 (333-295226) declared effective
  • Prior S-3 filings registered ~22.8M shares (Jan 30, 2026) and ~5.3M shares (Apr 22, 2026) for resale
  • Selling stockholders include Ascent Partners (equity line) and others from Sarborg acquisition
  • Company will not receive proceeds from resales

Financial Impact

Up to ~28 million shares registered for resale, causing potential dilution of over 100% of current float (based on prior S-3 disclosures)

dilutionstock price

Risk Factors

  • Massive dilution from resale of registered shares
  • Continuous selling pressure from equity line draws
  • Low liquidity amplifying price impact of any sales

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001441
Document: 9999999995-26-001441-index.html9999999995-26-001441
Document: 9999999995-26-001441.txt9999999995-26-001441
3 reports for CDTTW
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for CDTTW — sortable, filterable
TypeNow
May 15, 2026
20w ago
8-K
NEUTRAL ★ 3/10
$0.006600 $0.0149▲ +125.76%▲ +124.18%—
May 4, 2026
21w ago
EFFECT
BEARISH ★ 6/10
$0.006600 $0.006600· 0.00%▲ +5.65%—
Apr 22, 2026
23w ago
S-3
BEARISH ★ 7/10
$0.006600 $0.006600· 0.00%▲ +3.17%—
Showing 3 of 3

US Market Status

Market Closed — Opens Mon (37h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access